查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649513

药物释放型支架市场：预测（2025-2030 年）

Drug Eluting Stent Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

药物释放型支架市场预计将从 2025 年的 114.99 亿美元成长到 2030 年的 170.49 亿美元，预测期内的复合年增长率为 8.20%。

药物释放型支架是一种由金属製成的半刚性管状装置，其中装有药物，可缓慢释放药物以防止狭窄或动脉阻塞復发。支架设计和输送技术的最新创新有望显着降低即使在复杂病变中也会出现血管再阻塞率，从而降低早期和晚期血栓症的发生率。全球老年人口的增加是药物释放型支架市场的主要动力。随着年龄的增长，人们更容易患上血管疾病，从而增加了对药物释放型支架等有效治疗选择的需求。此外，久坐的生活方式和不良的饮食习惯也导致动脉粥状硬化病例的增加，其特征是动脉中斑块的堆积。

药物释放型支架市场驱动因素

  • 技术进步：从标准血管成形术到药物释放型支架 (DES) 的转变代表了治疗方案的重大进步。透过将药物治疗直接纳入支架，这种微创方法提供了许多好处，包括对血管的压力更小、恢復时间更快、併发症风险更低。例如，Orsiro Mission 代表了将药物直接输送到目标动脉的技术突破，从而改善了患者的治疗效果。随着医疗专业人员寻求更有效、更少侵入性的动脉疾病治疗方法，此类创新解决方案的成功实施可能会促进市场发展。

地理视角

  • 北美预计领先：预计预测期内北美将占据药物释放型支架市场的大部分份额。这一增长归因于优惠的报销政策和该地区动脉相关疾病发病率的上升。此外，药物释放型支架技术的进步和强大的医疗保健基础设施也促进了市场的扩张。根据《美国心臟病学会杂誌》 2023 年 2 月发表的一篇文章，对于 10 年预测风险较高的人群，美国粥状硬化性心血管疾病的发生率为每 1,000 人年 2.60 例。这项统计数据凸显了对药物释放型支架等有效治疗方案的需求日益增长。

随着老化人口增加，罹患冠状动脉疾病 (CAD) 等心血管疾病的可能性也随之增加，老年患者对药物释放型支架的需求也随之增加。研究表明，CAD 影响约 50% 的老年女性和 70% 至 80% 的老年男性。总体而言，技术创新不断提升和心血管疾病发病率不断上升等因素预计将推动药物释放型支架市场的成长，尤其是在北美。

为什么要购买这份报告？

  • 深刻的分析：涵盖主要地区和新兴地区，您可以获得对客户细分、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔的深入市场洞察。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第 5 章药物释放型支架市场（依涂层类型）

  • 介绍
  • 聚合物基涂料
  • 无聚合物涂料

第六章药物释放型支架市场（依应用）

  • 介绍
  • 冠状动脉疾病 (CAD)
  • 周边动脉疾病(PAD)

第 7 章药物释放型支架市场（以最终用户划分）

  • 介绍
  • 医院
  • 门诊手术中心
  • 其他的

第 8 章药物释放型支架市场（按区域）

  • 介绍
  • 北美洲
    • 按涂层类型
    • 按应用
    • 按最终用户
    • 按国家
  • 南美洲
    • 按涂层类型
    • 按应用
    • 按最终用户
    • 按国家
  • 欧洲
    • 按涂层类型
    • 按应用
    • 按最终用户
    • 按国家
  • 中东和非洲
    • 按涂层类型
    • 按应用
    • 按最终用户
    • 按国家
  • 亚太地区
    • 按涂层类型
    • 按应用
    • 按最终用户
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Abbott Cardiovascular
  • Boston Scientific Corporation
  • Medtronic Plc
  • Biotronik
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Biosensors International
  • Alvimedica
  • Lepu Medical Technology
  • MedicalExpo
  • Cook Medical
  • B. Braun
  • Biotronik
  • MicroPort Scientific Corporation
  • Sahajanand Medical Technologies
简介目录
Product Code: KSI061617277

The Drug eluting stent market is projected to grow at a CAGR of 8.20% over the forecast period, increasing from US$11.499 billion in 2025 to US$17.049 billion by 2030.

A drug-eluting stent is a metallic, semi-rigid tubular device that has a drug attached to it, allowing for a slow release of medication to prevent the recurrence of stenosis or arterial obstruction. Recent innovations in stent designs and delivery technologies are expected to significantly reduce the restenosis rate, even in complex lesions, thereby decreasing the incidence of both early and late thrombosis. The growing geriatric population worldwide is a major driver for the drug-eluting stent market, as the likelihood of developing vascular diseases increases with age, leading to greater demand for effective treatment options like drug-eluting stents. Additionally, sedentary lifestyles and poor dietary habits are contributing to a rise in cases of atherosclerosis, characterized by plaque buildup in the arteries.

Drivers of the Drug-Eluting Stent Market

  • Technological Advancements: The transition from standard angioplasty to drug-eluting stents (DES) represents a significant advancement in treatment options. By integrating medication therapy directly onto the stent, this minimally invasive approach offers numerous benefits, including reduced stress on blood vessels, faster recovery times, and lower complication risks. For example, the Orsiro Mission represents a technological breakthrough that delivers drugs directly into target arteries, thereby improving patient outcomes. The successful implementation of such innovative solutions is likely to increase market activity as healthcare professionals seek more effective and less invasive treatments for arterial disorders.

Geographical Outlook

  • North America Expected to Lead: North America is projected to hold a substantial share of the drug-eluting stent market during the forecast period. This growth can be attributed to favorable reimbursement policies and a rising incidence of artery-related diseases in the region. Furthermore, advancements in drug-eluting stent technology and a robust healthcare infrastructure have contributed to market expansion. According to the Journal of the American College of Cardiology published in February 2023, the incidence rate of atherosclerotic cardiovascular disease in the United States was 2.60 per 1,000 person-years among individuals with high 10-year predicted risk. This statistic underscores the growing need for effective treatment options like drug-eluting stents.

As the aging population is more susceptible to cardiovascular diseases such as coronary artery disease (CAD), there is an increasing demand for drug-eluting stents among older patients. Studies indicate that CAD affects approximately 50% of older women and 70%-80% of older men. Additionally, Canada's elderly population is projected to grow significantly over the next two decades, further driving demand for these medical devices.In summary, factors such as rising technological innovations and an increasing prevalence of cardiovascular diseases are expected to propel growth in the drug-eluting stent market, particularly in North America.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Drug eluting stent market is segmented and analyzed as follows:

By Coating Type

  • Polymer-Based Coating
  • Polymer-Free Coating.

By Application

  • Coronary Artery Disease (CAD)
  • Peripheral Artery Disease (PAD)

By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Others
  • Middle East and Africa
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. DRUG ELUTING STENT MARKET BY COATING TYPE

  • 5.1. Introduction
  • 5.2. Polymer-Based Coating
  • 5.3. Polymer-Free Coating

6. DRUG ELUTING STENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Coronary Artery Disease (CAD
  • 6.3. Peripheral Artery Disease (PAD)

7. DRUG ELUTING STENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Ambulatory Surgical Centers
  • 7.4. Others

8. DRUG ELUTING STENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Coating Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Coating Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Coating Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. UK
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Coating Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. UAE
      • 8.5.4.2. Israel
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Coating Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott Cardiovascular
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic Plc
  • 10.4. Biotronik
  • 10.5. Terumo Corporation
  • 10.6. MicroPort Scientific Corporation
  • 10.7. Biosensors International
  • 10.8. Alvimedica
  • 10.9. Lepu Medical Technology
  • 10.10. MedicalExpo
  • 10.11. Cook Medical
  • 10.12. B. Braun
  • 10.13. Biotronik
  • 10.14. MicroPort Scientific Corporation
  • 10.15. Sahajanand Medical Technologies